Latest Breaking News On - Steven kirshblum - Page 1 : vimarsana.com

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims.

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Award Will Support 2nd Annual Spinal Cord Injury Investor Symposium To Be Held June 26 and 27, 2024 .

Kessler Foundation receives $3M to expand neurotrauma research

The Kessler Foundation received $3 million in federal funding to expand its research to help adults stay in the workforce after neurotrauma. 

Kessler Foundation awarded Social Security Administration funding to expand research for improving employment outcomes following neurotrauma

/PRNewswire/ Kessler Foundation has received $3,000,000 from the Social Security Administration s (SSA) Interventional Cooperative Agreement Program (ICAP).

Kessler Foundation awarded Social Security Administration funding to expand research for improving employment outcomes following neurotrauma

Kessler and BrainQ partner on a national trial of breakthrough device to improve recovery after stroke

Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively "Kessler") are enrolling participants in a national trial of a breakthrough device for improving recovery after stroke. Kessler locations in West Orange and Saddle Brook, NJ, are among the 20 sites across the U.S. participating in the EMAGINE Stroke Recovery Trial, which pairs therapeutic exercise with stimulation of the brain through an investigational wearable device.

New collaborative work wins Neuromod Prize to accelerate the development of neuromodulation therapies

The pioneering collaborative work being performed by Kessler Foundation scientists in the Tim and Caroline Reynolds Center for Spinal Stimulation team has been recognized with the Neuromod Prize, a new initiative from the National Institutes of Health (NIH) Common Fund's Stimulating Peripheral Activity to Relieve Conditions (SPARC) program.

NervGen Pharma Corp. (via Public) / NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board

Electromagnetic stimulation may improve arm and hand function after spinal cord injury

 E-Mail IMAGE: A research participant wearing the BrainQ System, an AI-powered device that delivers electromagnetic stimulation to the upper extremity of individuals with impaired motor abilities. view more  Credit: BrainQ Technologies East Hanover, NJ. January 14, 2021. Ghaith Androwis, PhD, and Steven Kirshblum, MD, received a grant from BrainQ Technologies to study a potential treatment for arm and hand dysfunction in individuals with chronic spinal cord injury. The study is titled, The safety and effectiveness of the use of a brain-computer interface-based electromagnetic field treatment in the management of patients with chronic spinal cord injury: A pilot study. Dr. Androwis is a research scientist in the Center for Mobility and Rehabilitation Engineering Research at Kessler Foundation. Dr. Kirshblum is senior medical officer and director of the Spinal Cord Injury Program for Kessler Institute for Rehabilitation, chief academic officer for the Select Medical R